Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells.
about
PAPA-1 Is a nuclear binding partner of IGFBP-2 and modulates its growth-promoting actionsDuplication of the IGFBP-2 gene in teleost fish: protein structure and functionality conservation and gene expression divergenceInsulin-like growth factor binding protein 2 promotes ovarian cancer cell invasionIGF-Binding Protein 2 - Oncogene or Tumor Suppressor?The insulin-like growth factor system in cancerExogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathwayInsulin-like growth factor binding proteins: a structural perspective.Molecular profiling reveals similarities and differences between primitive subsets of hematopoietic cells generated in vitro from human embryonic stem cells and in vivo during embryogenesisRole of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3Expression of insulin-like growth factor binding protein-2 in gastric carcinoma and its relationship with cell proliferation.Insulin-like growth factor binding proteins increase intracellular calcium levels in two different cell lines.IGF binding protein 2 supports the survival and cycling of hematopoietic stem cellsDifferences in IGF-axis protein expression and survival among multiethnic breast cancer patients.High IGFBP2 expression correlates with tumor severity in pediatric rhabdomyosarcoma.Genetic variation in IGFBP2 and IGFBP5 is associated with breast cancer in populations of African descent.HPV16 Down-Regulates the Insulin-Like Growth Factor Binding Protein 2 to Promote Epithelial Invasion in Organotypic Cultures.IGFBP-2 - taking the lead in growth, metabolism and cancerIGFBP-2 and -5: important regulators of normal and neoplastic mammary gland physiologySerum IGFBP-2 and Risk of Atypical Hyperplasia of the BreastInsulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB networkInsulin-like growth factor factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling.Insulin-like growth factor binding protein 2 promotes glioma development and progressionDo insulin-like growth factor associated proteins qualify as a tumor marker? Results of a prospective study in 163 cancer patients.Insulin-like growth factor (IGF) binding protein 2 functions coordinately with receptor protein tyrosine phosphatase β and the IGF-I receptor to regulate IGF-I-stimulated signaling.IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma.Angiopoietin-like 5 and IGFBP2 stimulate ex vivo expansion of human cord blood hematopoietic stem cells as assayed by NOD/SCID transplantationThe role of insulin-like growth factor binding proteins.Autoantibodies against insulin-like growth factor‑binding protein-2 as a serological biomarker in the diagnosis of lung cancerApoptosis Effect of Girinimbine Isolated from Murraya koenigii on Lung Cancer Cells In VitroPrimary pigmented nodular adrenocortical disease reveals insulin-like growth factor binding protein-2 regulation by protein kinase AInsulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer.Insulin-like growth factor-binding protein 2 secreted by a tumorigenic cell line supports ex vivo expansion of mouse hematopoietic stem cells.Prohibitin-2 binding modulates insulin-like growth factor-binding protein-6 (IGFBP-6)-induced rhabdomyosarcoma cell migration.The heparin-binding domains of IGFBP-2 mediate its inhibitory effect on preadipocyte differentiation and fat development in male mice.AMPA receptors promote perivascular glioma invasion via beta1 integrin-dependent adhesion to the extracellular matrix.Deregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancer in vitro.IGF binding protein 2 is a cell-autonomous factor supporting survival and migration of acute leukemia cellsIGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions.Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
P2860
Q24309255-24DF9BDC-1B8C-45F0-AEEC-B932C9C1E8C2Q24336134-BD2D8A7C-339B-4A54-A632-589B614F5D86Q24805939-0974A01F-A077-45CE-8DA4-52B0217C49DCQ27003443-64A8A369-0E72-42DD-BB7D-A26DDD100BFBQ27013945-A97E25EA-B583-4F9C-86A0-8C9672B36D13Q30402547-A0AC205D-2CB6-4543-BCBE-F6F40822A6E2Q30417447-FB5EB57A-1651-4886-ACFC-5CF3FC5F8B24Q33376919-81BEA5C6-FAF7-42D4-ACF4-076B50E915ACQ33745176-989889FE-239A-4847-8CB8-A48BB5A8DF3AQ33869094-6BE81A37-5666-421D-9B35-B3F2F52FC1A1Q34634999-764A7271-4AD0-48CC-B3E7-7DB9D2AD3453Q35230193-430B4D4B-38ED-4650-B496-C5B9E87D4072Q35236778-B2DDED13-83E0-4955-BD96-8C9748B6CDD9Q35474529-C72CA865-E103-4E04-938D-776CD5401B63Q35524233-BBF0A965-7941-4840-B5F6-B87C98B9D6E3Q35672982-61609D5A-8B22-4005-AF99-CDCE2E4A4F09Q35690628-74886696-0976-42D4-9E7A-F07615A91B6FQ35690638-63DC9FCE-DA3D-41E6-A7E5-EAFFACEC5963Q35729809-6BA900BB-F312-4F57-84EE-7A4DD94BF031Q35807732-63885F1C-9071-4ACC-9C4E-D4C9D7B2D009Q35869171-6BB7E930-1A2D-4621-BAC5-B06D4DBE668BQ35880328-0AA935A6-A6D5-4C64-AD43-527383CBA8E8Q36105839-4322DA8C-D7F2-4D06-9E5F-A36EB2BD11EEQ36276736-4506BFE7-6CCA-4E50-BDCA-E979245F6E7AQ36413323-4DFB94D2-4F6F-499B-9DC9-C6615D5D7D62Q36508850-4F7493E9-3781-40A0-B18F-654391A98E2EQ36626462-DCBF29DB-A741-46A7-A923-3A826DF9D9C9Q36642867-6849B5D2-5282-43E0-9109-8C78F841C26DQ36723073-AFAAEE2E-F0A7-4B86-B511-0ACED45EA1E6Q36960838-35B56916-4D4E-4227-8AF2-30B631C515FCQ37001399-F1162138-B410-4BBB-9E40-1E8AA817F093Q37182033-CCF3D7D7-93A5-42AE-948E-F65ACA2CD00DQ37226250-5ABA080F-F17C-4F05-BAEA-CD3B94EDDF1DQ37240147-5BDD661F-73B8-4C19-BAA4-E56D23347438Q37284251-DF3AA1A4-10E2-420E-8211-BEBFAEB5EFA0Q37362627-AF3CAD97-DC8A-4909-8F21-1CF94D638664Q37365497-500F23A0-1475-45D0-B36F-8BA4E4111697Q37381182-9ECB2019-E890-49F8-AC2F-9ECF363AC521Q37418923-A919FFBB-4C34-4FA8-92CA-3EEE86C82702Q37424063-E5109F65-1078-4FA4-9865-13A4EB30A99C
P2860
Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells.
@en
type
label
Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells.
@en
prefLabel
Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells.
@en
P2093
P356
P1476
Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells.
@en
P2093
Elmlinger MW
Langkamp M
Rauschnabel U
P304
P356
10.1677/JME.0.0320859
P577
2004-06-01T00:00:00Z